What targeted drugs are bosutinib/bosutinib and cabozantinib?

Bosutinib/Bosutinib and Cabozantinib are both tyrosine kinase inhibitors (TKIs), but they have significant differences in indications, mechanisms of action, and clinical applications.

Bosutinib is mainly used to treat chronic myelogenous leukemia (CML), especially those patients who have poor response or resistance to other TKI treatments. Its mechanism of action is to prevent the proliferation and survival of cancer cells by inhibiting the activity of BCR-ABL1 fusion protein. Bosutinib has shown good efficacy in clinical trials and is considered one of the effective options for the treatment of CML.

In contrast, cabozantinib is mainly used to treat a variety of solid tumors, including thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Its mechanism of action is more extensive, not only inhibiting the activities of MET and VEGFR, but also affecting other related signaling pathways, thereby inhibiting tumor growth and metastasis. Due to its broad spectrum of action, cabozantinib has shown promising results in the treatment of many types of cancer.

In terms of side effects, common adverse reactions of bosutinib include diarrhea, abnormal liver function and thrombocytopenia, while cabozantinib may cause hypertension, fatigue, loss of appetite and liver function damage. Therefore, when using these two drugs, doctors need to weigh the benefits of treatment against the potential risks based on the patient's specific situation.

Additionally, bosutinib and cabozantinib are used differently. Bosutinib is usually given in oral form, and patients need to be monitored regularly under the guidance of a doctor to evaluate efficacy and adjust dosage. Cabozantinib is also taken orally, but its usage guidelines and treatment options for different cancer types are more complex.

Reference materials:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/bosutinib

Reference materials:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/cabozantinib-tablets